Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease

Abstract Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear. The aim of this study was to compare the efficacy...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Marta Colaneri, Giovanni Scaglione, Federico Fassio, Lucia Galli, Alessia Lai, Annalisa Bergna, Arianna Gabrieli, Maciej Tarkowski, Carla Della Ventura, Valeria Colombo, Laura Cordier, Davide Bernasconi, Mario Corbellino, Gianfranco Dedivitiis, Silvia Borghetti, Debora Visigalli, Salvatore Sollima, Giacomo Casalini, Giuliano Rizzardini, Andrea Gori, Spinello Antinori, Agostino Riva, Monica Schiavini
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2024-03-01
Цуврал:	Virology Journal
Нөхцлүүд:	COVID-19 Monoclonal antibodies Time to negativization Immunosuppression Nirmatrelvir/Ritonavir
Онлайн хандалт:	https://doi.org/10.1186/s12985-024-02333-x
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!